161 related articles for article (PubMed ID: 35617521)
1. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
Zhang Y; Houchen CW; Li M
Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
[TBL] [Abstract][Full Text] [Related]
4. Organoid models for translational pancreatic cancer research.
Tiriac H; Plenker D; Baker LA; Tuveson DA
Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
[TBL] [Abstract][Full Text] [Related]
5. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
[TBL] [Abstract][Full Text] [Related]
6. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
8. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems.
Peschke K; Jakubowsky H; Schäfer A; Maurer C; Lange S; Orben F; Bernad R; Harder FN; Eiber M; Öllinger R; Steiger K; Schlitter M; Weichert W; Mayr U; Phillip V; Schlag C; Schmid RM; Braren RF; Kong B; Demir IE; Friess H; Rad R; Saur D; Schneider G; Reichert M
EMBO Mol Med; 2022 Apr; 14(4):e14876. PubMed ID: 35119792
[TBL] [Abstract][Full Text] [Related]
9. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
10. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Yomtoubian S; Ng I; Tiriac H; Lowy AM; Zou J; Engle DD
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38051586
[TBL] [Abstract][Full Text] [Related]
11. [Organoids from pancreatic ductal adenocarcinoma].
Dusetti N; Iovanna J
Med Sci (Paris); 2020 Jan; 36(1):57-62. PubMed ID: 32014099
[TBL] [Abstract][Full Text] [Related]
12. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
[TBL] [Abstract][Full Text] [Related]
13. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
Sandhya S; Hogenson TL; Fernandez-Zapico ME
EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
[TBL] [Abstract][Full Text] [Related]
15. PDX-derived organoids model in vivo drug response and secrete biomarkers.
Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
[TBL] [Abstract][Full Text] [Related]
16. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
17. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
19. State-matched organoid models to fight pancreatic cancer.
Melzer MK; Roger E; Kleger A
Trends Cancer; 2022 Jun; 8(6):445-447. PubMed ID: 35370114
[TBL] [Abstract][Full Text] [Related]
20. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA
Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
